7 results about "Tricine" patented technology

This invention relates to a method for preparing and applying a radiopharmaceutical containing an interleukin-2 mutant, specifically belonging to the field of molecular biology pharmaceuticals. The radiopharmaceutical comprises the interleukin-2 mutant (sIL-2), a radionuclide, and a chelating agent. The radionuclide is labeled with GGGGK-HYNIC and linked to the LPETG tag of sIL-2 under the action of Sortase A enzyme. This invention is based on a radiopharmaceutical prepared from an interleukin-2 mutant. Through protein sequence mutation, the resulting mutant sIL-2 exhibits lower toxicity than interleukin-2 (IL-2) and higher receptor affinity, which is more conducive to T cell imaging in vivo. Site-specific labeling of the radionuclide using Sortase A enzyme and residual cysteine ​​residues at the C-terminus of the protein structure ensures the homogeneity of the prepared radiopharmaceutical. Furthermore, HYNIC is used as a bifunctional chelating agent, and TPPTS and tricine are used as co-ligands to achieve… 99m The Tc-HYNIC core exhibits better in vivo and in vitro stability.

An RGD polypeptide-containing composition and use thereof. The composition contains 1-3 parts by weight of a compound of formula I, 50-200 parts by weight of TPPTS, 2-250 parts by weight of Tricine, and a succinate buffer system, and the amount of the succinate buffer system is such that the pH of the composition is 4.0-7.0. The composition has excellent integrity and stability, and can be used for preparing SPECT imaging agents for tumor diagnosis.

To provide cationic lipids which are useful for delivery and expression of mRNA and encoded protein as a component of a liposomal delivery vehicle, and useful for treating diseases, disorders and conditions associated with deficiency of proteins.SOLUTION: The invention provides a cationic lipid represented by Formula (A) or a pharmaceutically acceptable salt thereof. (In the formula: X1A is O or NR1A; X1B is a bond, C(O), CH2CO2, CH2C(O); one of X2A and X2B is O and the other is a bond; one of X3A and X3B is O and the other is a bond; one of X4A and X4B is O and the other is a covalent bond; and the cationic lipid comprises at least one ionizable nitrogen-containing group.)SELECTED DRAWING: None

The invention is suitable for the field of molecular biology, and provides an improved electrophoresis liquid and polyacrylamide gel combination and application thereof.The improved electrophoresis liquid is prepared from 25 mM of Tris, 192 mM of glycine, 0.1% (w / v) of SDS and 30-50 mM of Tricine, and polyacrylamide gel is prepared from separation gel and concentrated gel; 30-50 mM of Tricine is added into a traditional formula, an improved electrophoresis solution is prepared, the fringe effect can be reduced by optimizing electric field distribution, 5% (v / v) of glycerin is added into 11%-12% (w / v) of acrylamide / bisacrylamide (29: 1) separation gel, the gel stability is enhanced, the heat effect and pore deformation are reduced, CV is reduced to 5-6% through improved combination, and the transfer efficiency is improved to gt; the method is especially suitable for 15-100 kDa protein analysis.

Disclosed are cationic lipids which are compounds of Formula A. (A) Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins. X2A X1A X4A X3A X1B n n n X2B O X3BO X4B O R2 R4 R3 R1 O X3A O O X1A X 1B 20 26 20 48 02 22 J un 2 02 6 2 0 2 6 2 0 4 8 0 2 2 2 2 0 2 6 J u n O O O 1 A 1 B

The present invention provides, in part, tricine and citrate lipids, or pharmaceutically acceptable salts thereof. The compounds provided herein, comprising compounds of formula (A), may be useful for the delivery and expression of mRNA and encoded proteins, for example, as components of liposome delivery vehicles, and therefore may be useful in treating a variety of diseases, disorders and conditions, including those associated with the deficiency of one or more proteins. [Case 1] TIFF2026524782000711.tif22170

The invention relates to the technical field of biosynthesis, and provides a method for catalyzing selective oxidation of limonene. The method comprises the following steps: mixing limonene, non-specific peroxygenase, a solvent and a buffer solution to prepare a reaction solution; under the condition of 25-35 DEG C, H2O2 is added to start oxidation reaction; wherein the buffer solution comprises one or more of a Tris buffer solution and a Tricine buffer solution. According to the present invention, by changing the type of the buffer solution in the reaction system, the buffer solution can directly influence the microenvironment of the non-specific peroxygenase activity center so as to promote the oxidation of the specific site in the limonene molecule, and selectively synthesize the 1, 2-epoxy limonene; therefore, under the condition that non-specific peroxygenase is not modified, oxygen-containing compounds such as 1, 2-epoxy limonene and the like can be rapidly and efficiently catalyzed and synthesized.